[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 825000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 338000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 63, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.52, "open": 2.52, "dayLow": 2.26, "dayHigh": 2.535, "regularMarketPreviousClose": 2.52, "regularMarketOpen": 2.52, "regularMarketDayLow": 2.26, "regularMarketDayHigh": 2.535, "payoutRatio": 0.0, "beta": 1.601, "forwardPE": -1.8267716, "volume": 567220, "regularMarketVolume": 567220, "averageVolume": 306304, "averageVolume10days": 553200, "averageDailyVolume10Day": 553200, "bid": 2.27, "ask": 2.37, "bidSize": 1, "askSize": 1, "marketCap": 55146168, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 6.01, "fiftyDayAverage": 2.9006, "twoHundredDayAverage": 2.466895, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 52659780, "profitMargins": 0.0, "floatShares": 13611085, "sharesOutstanding": 23769900, "sharesShort": 545481, "sharesShortPriorMonth": 799531, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0275, "heldPercentInsiders": 0.11553001, "heldPercentInstitutions": 0.25471002, "shortRatio": 2.06, "shortPercentOfFloat": 0.030299999, "impliedSharesOutstanding": 25819000, "bookValue": -1.829, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -33793000, "trailingEps": -2.21, "forwardEps": -1.27, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToEbitda": -3.727, "52WeekChange": 0.41033435, "SandP52WeekChange": 0.16844666, "quoteType": "EQUITY", "currentPrice": 2.32, "targetHighPrice": 46.0, "targetLowPrice": 25.0, "targetMeanPrice": 35.0, "targetMedianPrice": 34.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 2910000, "totalCashPerShare": 0.148, "ebitda": -14127500, "totalDebt": 9854000, "quickRatio": 0.072, "currentRatio": 0.113, "returnOnAssets": -1.74879, "freeCashflow": 8726875, "operatingCashflow": -11912000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -7.93651, "regularMarketPrice": 2.32, "marketState": "CLOSED", "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "corporateActions": [], "postMarketTime": 1756511544, "regularMarketTime": 1756497601, "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "postMarketChangePercent": 0.8620682, "postMarketPrice": 2.34, "postMarketChange": 0.01999998, "regularMarketChange": -0.2, "regularMarketDayRange": "2.26 - 2.535", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 306304, "fiftyTwoWeekLowChange": 1.2199999, "fiftyTwoWeekLowChangePercent": 1.1090908, "fiftyTwoWeekRange": "1.1 - 6.01", "fiftyTwoWeekHighChange": -3.6900003, "fiftyTwoWeekHighChangePercent": -0.6139767, "fiftyTwoWeekChangePercent": 41.033436, "earningsTimestamp": 1755520200, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "earningsCallTimestampStart": 1755691200, "earningsCallTimestampEnd": 1755691200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.21, "epsForward": -1.27, "epsCurrentYear": 0.15, "priceEpsCurrentYear": 15.466665, "fiftyDayAverageChange": -0.5806, "fiftyDayAverageChangePercent": -0.2001655, "twoHundredDayAverageChange": -0.14689517, "twoHundredDayAverageChangePercent": -0.059546582, "priceToBook": -1.2684526, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2025-08-29", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-30"}]